(Q34649847)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627672%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

review article

1 reference

title

RB101-mediated protection of endogenous opioids: potential therapeutic utility? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627672%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

0 references

Emily M Jutkiewicz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627672%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627672%20AND%20SRC:MED&resulttype=core&format=json

CNS Neuroscience & Therapeutics

2 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627672%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627672%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627672%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

192-205

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627672%20AND%20SRC:MED&resulttype=core&format=json

CB1 receptor knockout mice show similar behavioral modifications to wild-type mice when enkephalin catabolism is inhibited.

2 January 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00011.X

Involvement of neutral endopeptidase in neoplastic progression

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00011.X

The effects of RB101, a mixed inhibitor of enkephalin-catabolizing enzymes, on carrageenin-induced spinal c-Fos expression are completely blocked by beta-funaltrexamine, a selective mu-opioid receptor antagonist

21 January 2018

1 reference

12 December 2020

Cholecystokinin/opioid interactions

1 reference

12 December 2020

Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses

1 reference

12 December 2020

Effects of the potent analgesic enkephalin-catabolizing enzyme inhibitors RB101 and kelatorphan on respiration

1 reference

12 December 2020

Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats

1 reference

12 December 2020

Facilitation of enkephalins catabolism inhibitor-induced antinociception by drugs classically used in pain management

1 reference

12 December 2020

Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats

1 reference

12 December 2020

RB101(S), a dual inhibitor of enkephalinases does not induce antinociceptive tolerance, or cross-tolerance with morphine: a c-Fos study at the spinal level.

1 reference

12 December 2020

Further evidence for the interaction of mu- and delta-opioid receptors in the antinociceptive effects of the dual inhibitor of enkephalin catabolism, RB101(S). A spinal c-Fos protein study in the rat under carrageenin inflammation

1 reference

12 December 2020

Vocalizations during withdrawal from opiates and cocaine: possible expressions of affective distress

1 reference

12 December 2020

Pain management by a new series of dual inhibitors of enkephalin degrading enzymes: long lasting antinociceptive properties and potentiation by CCK2 antagonist or methadone

1 reference

12 December 2020

Behavioral depression during cocaine withdrawal is associated with decreased spontaneous activity of ventral tegmental area dopamine neurons

1 reference

12 December 2020

In vivo occupation of mouse brain opioid receptors by endogenous enkephalins: blockade of enkephalin degrading enzymes by RB 101 inhibits [3H]diprenorphine binding

1 reference

12 December 2020

Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation

1 reference

12 December 2020

Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation.

1 reference

12 December 2020

"Mixed inhibitor-prodrug" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes

1 reference

12 December 2020

Delta-opioid agonists: differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats

1 reference

12 December 2020

Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine

1 reference

12 December 2020

Lack of physical dependence in mice after repeated systemic administration of the mixed inhibitor prodrug of enkephalin-degrading enzymes, RB101

1 reference

12 December 2020

Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents

1 reference

12 December 2020

Membrane bound members of the M1 family: more than aminopeptidases

1 reference

12 December 2020

Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats

1 reference

12 December 2020

Facilitation of enkephalins-induced delta-opioid behavioral responses by chronic amisulpride treatment.

1 reference

12 December 2020

Physiological control of emotion-related behaviors by endogenous enkephalins involves essentially the delta opioid receptors

1 reference

12 December 2020

Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects

1 reference

12 December 2020

Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: in vitro and in vivo studies.

1 reference

12 December 2020

Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys

1 reference

12 December 2020

Involvement of central mu and delta opioid receptors in mediating the reinforcing effects of beta-endorphin in the rat.

1 reference

12 December 2020

Synthesis, biochemical and pharmacological properties of BUBUC, a highly selective and systemically active agonist for in vivo studies of delta-opioid receptors

1 reference

12 December 2020

Assessment of the abuse potential of acetorphan, an enkephalinase inhibitor

1 reference

12 December 2020

Comparison of selective and complete inhibitors of enkephalin-degrading enzymes on morphine withdrawal syndrome

1 reference

12 December 2020

Motivational properties of opioids: evidence that an activation of delta-receptors mediates reinforcement processes

1 reference

12 December 2020

Autoradiographic comparison of the distribution of the neutral endopeptidase "enkephalinase" and of mu and delta opioid receptors in rat brain

1 reference

12 December 2020

Enkephalin degrading enzyme inhibitors: a physiological way to new analgesics and psychoactive agents

1 reference

12 December 2020

Effects of kelatorphan and other peptidase inhibitors on the in vitro and in vivo release of methionine-enkephalin-like material from the rat spinal cord

1 reference

12 December 2020

Prevention of degradation of endogenous enkephalins produces inhibition of nociceptive neurones in rat spinal cord

1 reference

12 December 2020

Effect of inhibition of neuropeptidases on the pain threshold of mice and rats

1 reference

12 December 2020

A selective CCKB receptor antagonist potentiates, mu-, but not delta-opioid receptor-mediated antinociception in the formalin test

1 reference

12 December 2020

Assessment of endogenous enkephalins efficacy in the hot plate test in mice: comparative study with morphine

1 reference

12 December 2020

Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation

1 reference

12 December 2020

Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins

1 reference

12 December 2020

Effects of opioids and non-opioids on c-Fos-like immunoreactivity induced in rat lumbar spinal cord neurons by noxious heat stimulation.

1 reference

12 December 2020

Self-administration of morphine, DAMGO, and DPDPE into the ventral tegmental area of rats.

1 reference

12 December 2020

Assessment of physical dependence after continuous perfusion into the rat jugular vein of the mixed inhibitor of enkephalin-degrading enzymes, RB 101.

1 reference

12 December 2020

A nonpeptidic delta opioid receptor agonist, BW373U86, attenuates the development and expression of morphine abstinence precipitated by naloxone in rat.

1 reference

12 December 2020

Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice

1 reference

12 December 2020

Unlike morphine the endogenous enkephalins protected by RB101 are unable to establish a conditioned place preference in mice

1 reference

12 December 2020

Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects

1 reference

12 December 2020

Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist

1 reference

12 December 2020

The effects of dopamine D1 and D2 receptor antagonists on the rewarding effects of delta 1 and delta 2 opioid receptor agonists in mice

1 reference

12 December 2020

The dual peptidase inhibitor RB101 induces a long-lasting increase in the extracellular level of Met-enkephalin-like material in the nucleus accumbens of freely moving rats

1 reference

12 December 2020

1 reference

12 December 2020

Opposite role of delta 1- and delta 2-opioid receptors activated by endogenous or exogenous opioid agonists on the endogenous cholecystokinin system: further evidence for delta-opioid receptor heterogeneity.

1 reference

12 December 2020

Antidepressant-like effects of CCK(B) receptor antagonists: involvement of the opioid system

1 reference

12 December 2020

RB 101, a purported pro drug inhibitor of enkephalin metabolism, is antinociceptive in pregnant mice

1 reference

12 December 2020

Antinociceptive effects of RB101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats.

1 reference

12 December 2020

Pharmacodynamics and tolerance development during multiple intravenous bolus morphine administration in rats

1 reference

12 December 2020

CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level

1 reference

12 December 2020

CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins

1 reference

12 December 2020

Pain-suppressive effects on various nociceptive stimuli (thermal, chemical, electrical and inflammatory) of the first orally active enkephalin-metabolizing enzyme inhibitor RB 120.

1 reference

12 December 2020

Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model

1 reference

12 December 2020

Antinociception produced by the peptidase inhibitor, RB 101, in rats with adrenal medullary transplant into the spinal cord.

1 reference

12 December 2020

10.1111/J.1527-3458.2007.00011.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627672%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17627672%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

PubMed publication ID

17627672

1 reference